Product image of Octreoscan (Indium In-111 Pentetreotide) supplied by GNH India

Octreoscan

Active Ingredient:
Indium In-111 Pentetreotide
Origin:
EU

Octreoscan (Indium In-111 Pentetreotide)

Indium In-111 Pentetreotide, the active ingredient in Octreoscan, is a radiopharmaceutical presented as a diagnostic imaging agent for intravenous use. It binds to somatostatin receptors, enabling visualization of neuroendocrine tumors and related lesions in adult patients. GNH India supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH India supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Curium Netherlands B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Octreoscan is employed in the diagnostic pathway for somatostatin‑receptor positive neuroendocrine tumors. It helps clinicians locate and stage disease.

  • Neuroendocrine tumor imaging: Improves detection and anatomical mapping of primary and metastatic lesions.
  • Gastroenteropancreatic tumor assessment: Assists in evaluating tumor burden and treatment planning.
  • Carcinoid syndrome evaluation: Supports identification of occult disease sites contributing to hormonal symptoms.

How It Works

  • Indium In-111 Pentetreotide is a somatostatin analogue that binds with high affinity to somatostatin receptor subtypes (particularly SSTR2) expressed on neuroendocrine tumor cells. The indium‑111 radioisotope emits gamma photons, allowing external gamma‑camera imaging to visualize receptor‑positive tissue distribution after intravenous administration.

Side Effects

Adverse reactions are generally related to the radiopharmaceutical nature of the product and the injection procedure.

Common Side Effects

  • Nausea: Mild to moderate nausea reported in some patients.
  • Flushing: Transient facial or upper‑body flushing.
  • Injection site pain: Discomfort at the site of intravenous administration.
  • Headache: Mild headache occurring shortly after injection.

Serious or Rare Side Effects

  • Hypersensitivity reaction: Rash, urticaria, or anaphylaxis.
  • Severe hypotension: Marked drop in blood pressure post‑injection.
  • Bone marrow suppression: Transient reductions in blood cell counts.
  • Renal toxicity: Rare impairment of kidney function.

Precautions & Warnings

Before using Octreoscan, clinicians should evaluate patient suitability and monitor for potential adverse events.

  • Pregnancy testing: Perform before administration in women of childbearing potential.
  • Breastfeeding: Advise discontinuation during the imaging period.
  • Renal function: Assess baseline kidney function as the agent is renally excreted.
  • Prior radiation exposure: Consider cumulative dose from previous radiopharmaceuticals.
  • Store at ambient temperature: Keep in original container, protect from light and moisture.

Avoid Interactions

Octreoscan may interact with other agents that affect radiation exposure or renal clearance.

Major Interactions (Avoid)

  • Concurrent radiopharmaceutical therapy: Increases cumulative radiation dose.
  • Nephrotoxic drugs: May exacerbate renal clearance issues.

Moderate Interactions (Monitor Closely)

  • Diuretics: Can alter renal excretion rate.
  • ACE inhibitors: May affect blood pressure response post‑injection.
  • Antihistamines: May mask early signs of hypersensitivity.
  • Contrast agents: Potential additive radiation exposure during imaging.
  • Chemotherapy agents: Overlap in bone‑marrow suppression risk.

Frequently Asked Questions

Octreoscan is a radiopharmaceutical used primarily to locate and stage somatostatin‑receptor positive neuroendocrine tumors. It provides whole‑body imaging that helps physicians assess tumor spread, plan surgery or other therapies, and monitor disease progression.

Indium In-111 Pentetreotide is a somatostatin analogue that binds to somatostatin receptors on neuroendocrine tumor cells. The attached indium‑111 emits gamma radiation, which is captured by a gamma camera to produce detailed images of receptor‑bearing tissues.

The administered activity of Octreoscan is determined by the prescribing physician based on patient weight, age, and the specific imaging protocol. Dosage is individualized and should follow local regulatory and institutional guidelines.

Octreoscan is generally contraindicated in pregnancy because radiation exposure may affect the fetus. Women of childbearing potential should undergo pregnancy testing, and breastfeeding should be paused during the imaging period to avoid radiation transfer to the infant.

To order Octreoscan, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Octreoscan is a gamma‑emitting agent that provides high‑resolution whole‑body imaging, whereas newer PET agents such as Ga‑68 DOTATATE offer higher sensitivity and faster imaging times. Choice of agent depends on equipment availability, regulatory approval, and specific clinical questions.

Octreoscan should be stored at ambient temperature, protected from light, and kept in its original sealed container. Avoid exposure to moisture and handle with radiation safety precautions as recommended by local guidelines.

Octreoscan is administered intravenously by a qualified healthcare professional. After injection, imaging is typically performed 24 hours later to allow optimal tumor uptake and clearance of background activity.

Serious risks include hypersensitivity reactions, severe hypotension, and rare bone‑marrow suppression or renal toxicity. Patients should be monitored during and after injection for any signs of adverse reactions, and emergency measures should be readily available.

Octreoscan is contraindicated in patients with known hypersensitivity to the product, pregnant women, and individuals with severe renal impairment where clearance cannot be assured. Caution is also advised for patients who have recently received other radiopharmaceuticals.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Indium In-111 Pentetreotide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT